Patents by Inventor Tanja Maria Rosenkilde Kjaer

Tanja Maria Rosenkilde Kjaer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9833495
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 5, 2017
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Publication number: 20160129081
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Application
    Filed: November 16, 2015
    Publication date: May 12, 2016
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 9279010
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: January 30, 2014
    Date of Patent: March 8, 2016
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Patent number: 9217021
    Abstract: Treatment of an inflammatory bowel disease in a subject in need thereof by simultaneous or successive parenteral and oral administration of a mammalian beta defensin is described. Oral administration of mammalian beta defensin to a subject during remission to keep said subject suffering from IBD in remission, prolong remission in said subject suffering from IBD, to reduce the occurrence of relapse in said subject suffering from IBD, or any combination thereof, is also described.
    Type: Grant
    Filed: July 5, 2012
    Date of Patent: December 22, 2015
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 8802621
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: August 12, 2014
    Assignee: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20140213521
    Abstract: The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin.
    Type: Application
    Filed: July 5, 2012
    Publication date: July 31, 2014
    Applicant: NOVOZYMES A/S
    Inventors: Tanja Maria Rosenkilde Kjær, Birgitte Andersen, Karoline Sidelmann Brinch
  • Publication number: 20140135258
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: January 30, 2014
    Publication date: May 15, 2014
    Applicant: Defensin Therapeutics ApS
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20130172235
    Abstract: The present invention relates to treatment of an inflammatory bowel disease by simultaneous or successive parental and oral administration of a mammalian beta defensin.
    Type: Application
    Filed: July 6, 2012
    Publication date: July 4, 2013
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Birgitte Andersen, Karoline Sidelmann Brinch
  • Patent number: 8455235
    Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
    Type: Grant
    Filed: December 2, 2008
    Date of Patent: June 4, 2013
    Assignees: Novozymes A/S, Solvay Pharmaceuticals, GmbH
    Inventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
  • Publication number: 20130052213
    Abstract: The present invention relates a cleaved mammalian beta defensin with immunomodulatory properties. The cleaved or truncated peptides may be as potent as the full length mammalian beta defensins and may be used in the treatment of immunological and autoimmune disorders including but not limited to inflammatory bowel disease, and rheumatoid arthritis.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 28, 2013
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Birgitte Andersen
  • Publication number: 20120309686
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 6, 2012
    Applicant: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20120309678
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: July 9, 2012
    Publication date: December 6, 2012
    Applicant: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Patent number: 8232242
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 31, 2012
    Assignee: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Patent number: 8232248
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Grant
    Filed: July 17, 2009
    Date of Patent: July 31, 2012
    Assignee: Novozymes Adenium Biotech A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20110251139
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: June 13, 2011
    Publication date: October 13, 2011
    Applicant: NOVOZYMES A/S
    Inventors: TANJA MARIA ROSENKILDE KJAER, THOMAS KRUSE, PER HOLSE MYGIND, KAROLINE SIDELMANN BRINCH, SOEREN KJAERULFF, BIRGITTE ANDERSEN
  • Publication number: 20100322915
    Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.
    Type: Application
    Filed: December 2, 2008
    Publication date: December 23, 2010
    Applicants: Novozymes A/S, Solvay Pharmaceuticals, GmbH
    Inventors: Allan Svendsen, Lars Beier, Signe Eskildsen Larsen, Thomas Lenhard, Tanja Maria Rosenkilde Kjaer, Peter Colin Gregory
  • Publication number: 20100016232
    Abstract: The present invention relates to suppression of TNF-alpha activity with mammal beta defensins, which has utility in the treatment of pathological conditions associated with tumor necrosis factor alpha.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20100016230
    Abstract: The present invention relates to treatment of inflammatory bowel diseases with mammal beta defensins.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen
  • Publication number: 20100016231
    Abstract: The present invention relates to treatment of rheumatoid arthritis with mammal beta defensins.
    Type: Application
    Filed: July 17, 2009
    Publication date: January 21, 2010
    Applicant: Novozymes A/S
    Inventors: Tanja Maria Rosenkilde Kjaer, Thomas Kruse, Per Holse Mygind, Karoline Sidelmann Brinch, Soeren Kjaerulff, Birgitte Andersen